Tetra Radar · FDA Approvals · Decision date

neladalkib: FDA decision date

Royalty Pharma plc (RPRX) · 27 November 2026

In May 2026, Nuvalent announced the FDA accepted its NDA for neladalkib for filing and granted the application Priority Review with a PDUFA date of November 27, 2026.

Source: 10-Q of 5 August 2026

The decision is pending.

A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.

Get the Dispatch free.